AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02308293 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lay down comfortably
Description: rest
Study NCT00873197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only.
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_blood donor
Description: Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Roche - Cobas - Elecsys® HIV Duo .~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_Hospitalized patient
Description: All samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay for hospitalized patient.~* All initially reactive specimen results will be tested in duplicate per IFU .~* All RR specimens will be confirmed using testing including ImmunoBlot, Western Blot or HIV-1/HIV-2 differentiation test and HIV-1 PCR, RNA (if Immunoblot, WesternBlot or differentiation test is negative or indeterminate; if Immunoblot, WesternBlot or differentiation test is positive for HIV-2 then HIV-1 PCR will not be tested).
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_known HIV-1 antibody positives
Description: Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay .~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.~In case of discrepant results or concordant negative results between Access and Reference HIV Ag/Ab combo assay among known HIV-1 antibody positive patients, the IB/WB test will be repeated by the site to confirm sample status. If this IB/WB result is negative or indeterminate, the sample will be excluded from the statistical analysis
Study NCT04223063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: As per the intervention arm
Study NCT04137367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective bias modification
Description: In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
Study NCT04137367 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Affective bias modification
Description: In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
Study NCT03775499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Intervention 1 : BL NCC 2705 + Maltodextrin
Description: 2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
Study NCT01874249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic detailed information
Description: Electronic detailed information about non alcoholic fatty liver disease.
Study NCT01874249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAFLD Score
Description: diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
Study NCT01874249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transient elastography
Description: Transient elastography values greater than 8 kPa
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_known HIV-2 antibody positives
Description: Samples will be tested with both reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFU to determine non-reactive, initially reactive, and repeatedly reactive. Reference assay will be Abbott Architect HIV Ag/Ab combo assay.~* All initially reactive specimen results will be tested in duplicate per IFU .~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays.
Study NCT00592917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate and cholecalciferol
Description: one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
Study NCT03775499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 1 : Maltodextrin
Description: 2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
Study NCT01453998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Single dose, licensed formulation, intramuscular into right thigh
Study NCT01453998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: Single dose, licensed formulation, intramuscular into right thigh
Study NCT01453998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Single co-administered dose, intramuscular into left thigh
Study NCT01453998 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13
Description: Single co-administered dose, intramuscular into left thigh
Study NCT03775499 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Intervention 2 : BL NCC 2705 + Maltodextrin
Description: 2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
Study NCT03775499 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2 : Maltodextrin
Description: 2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
Study NCT04773548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-JIT
Description: Job interview with virtual interviewer
Study NCT01453998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK217744
Description: Single dose, investigational formulation A or B, intramuscular into right thigh
Study NCT00108953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
Description: Multi kinase inhibitor plus Chemotherapy
Study NCT00108953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin/Placebo
Description: Chemotherapy plus Placebo
Study NCT02644824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing (BiVp)
Description: BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
Study NCT02564588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4, 6, 8mg flexibly dosed once daily
Study NCT02564588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT03920865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: 5 milligram (mg) oral dose administered in fasted state
Study NCT04292197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-MC Compound
Description: 18-MC
Study NCT01842373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMX4
Study NCT01842373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLT
Study NCT00251693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
Study NCT00251693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00251693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
Study NCT00415870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Material
Description: Printed Material
Study NCT00415870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Weighing
Description: Weekly Weighing
Study NCT00415870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell phone will serve as a self monitoring device
Description: Cell phone will serve as a self monitoring device
Study NCT00415870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Text Message
Study NCT00415870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Goals via Cell Phone
Description: Diet Goals via Cell Phone
Study NCT00415870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Monitoring
Description: Food Monitoring
Study NCT02401243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous
Study NCT06524427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted lobectomy
Description: Patients will receive robot-assisted lobectomy using Da Vinci surgical system
Study NCT06524427 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted lobectomy
Description: Patients will receive video-assisted lobectomy
Study NCT03287973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
Study NCT03287973 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous positive airway pressure (CPAP)
Description: Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
Study NCT02266732 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stimuplex HNS 12
Study NCT01669642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
Study NCT00702247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplantation
Study NCT00004732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Endarterectomy (CEA)
Description: CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
Study NCT00004732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Description: CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
Study NCT03428256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow and THRIVE technique
Description: Nasal high flow humidified oxygen
Study NCT03428256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard anaesthetic face mask
Description: Oxygen delivery via an anaesthetic facemask
Study NCT02366390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative intervention
Description: Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
Study NCT00967109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L
Description: Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
Study NCT00967109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L
Description: Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
Study NCT02336139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/GS-5816
Description: 12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
Study NCT01015729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole/ASA Fixed Combination
Description: Capsule, oral, single dose
Study NCT01015729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: oral, single dose
Study NCT01956695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT01956695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01412372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: 2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
Study NCT01412372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is an inactive pill
Study NCT00141986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 2000 IU per day
Study NCT00141986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: 400 IU per os once daily
Study NCT02639052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: 10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
Study NCT02639052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
Study NCT01389583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: 70 mg/m2 60-min i.v. infusion weekly
Study NCT02192749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells
Study NCT03529578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dHACM
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
Study NCT01376193 — intervention group
Intervention type: DRUG
Intervention: Naratriptan
Description: Collection of safety data
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_known HIV-1 p24 Ag positive
Description: All samples will be tested with both Reference HIV Ag/Ab combo assay and Access HIV Ag/Ab combo assay according to respective IFUs/study guide to determine non-reactive (NR), initially reactive (IR), and repeatedly reactive (RR). Reference assay will be Abbott - ARCHITECT HIV Ag/Ab Combo Assay.~* Due to volume constraints, all known HIV-1 p24 Ag positive samples that will be tested during the EU HIV clinical trial will be tested in singulare only with the Reference HIV Ag/Ab combo assay, and in singulare and then in duplicate if IR with Access HIV Ag/Ab combo assay.~* For the known positive cohorts (sensitivity cohorts), samples will be identified as positive at enrollment/time of testing according to inclusion criteria prior to testing or in parallel of testing with Access and Reference HIV Ag/Ab combo assays
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_Canada's requirements_Blood donor
Description: To fit with Canada's requirements:~* 4,000 additional blood donor samples from geographically distinct regions will be collected and tested. Blood donor sample testing will be equally distributed over three blood donor sites, using 3 different lots of reagents: the first 2,000 blood donor samples from CE-marking study (out of the 6,000 tested) will be used plus the 4,000 additional blood donor samples.~* Retesting of 1000 blood donor samples will be done internally with 1 lot close to expiration to satisfy Canadian requirements
Study NCT03250949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant site over drilling protocol
Description: Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter
Study NCT03338868 — intervention group
Intervention type: OTHER
Intervention: Body composition
Description: evaluated by Bodystat®1500 Bio-impedance Analyzer
Study NCT00620659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0249
Description: Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
Study NCT00620659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
Study NCT00620659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: modafinil
Description: Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
Study NCT02929446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation
Description: Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
Study NCT02929446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilisation and breathing exercises
Description: Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
Study NCT01258166 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery or immobilization